Glendon French III Sells 67,813 Shares of Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation (NASDAQ:LUNG) CEO Glendon French III sold 67,813 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $1.43, for a total transaction of $96,972.59. Following the transaction, the chief executive officer owned 1,409,511 shares in the company, valued at approximately $2,015,600.73. This trade represents a 4.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pulmonx Price Performance

Shares of NASDAQ:LUNG opened at $1.61 on Friday. Pulmonx Corporation has a 52 week low of $1.31 and a 52 week high of $8.12. The company has a 50-day moving average price of $1.76 and a 200 day moving average price of $1.78. The company has a market cap of $66.41 million, a P/E ratio of -1.21 and a beta of 0.07. The company has a quick ratio of 4.15, a current ratio of 4.86 and a debt-to-equity ratio of 0.62.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, March 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.14. The company had revenue of $22.60 million for the quarter, compared to analysts’ expectations of $21.73 million. Pulmonx had a negative return on equity of 78.35% and a negative net margin of 59.67%. Research analysts predict that Pulmonx Corporation will post -1.55 earnings per share for the current year.

Hedge Funds Weigh In On Pulmonx

Several hedge funds have recently added to or reduced their stakes in LUNG. Susquehanna Portfolio Strategies LLC acquired a new position in Pulmonx during the fourth quarter worth about $133,000. Engineers Gate Manager LP acquired a new stake in shares of Pulmonx in the fourth quarter valued at approximately $106,000. ADAR1 Capital Management LLC increased its stake in shares of Pulmonx by 65.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 355,410 shares of the company’s stock worth $785,000 after purchasing an additional 140,913 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Pulmonx by 144.6% during the 4th quarter. AQR Capital Management LLC now owns 58,919 shares of the company’s stock worth $130,000 after purchasing an additional 34,828 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Pulmonx during the 4th quarter worth approximately $31,000. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

More Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Company closed a five‑year credit facility for up to $60 million (initial $40M draw used to refinance existing debt, $20M undrawn tied to revenue milestones), extending debt maturities to 2031 and improving near‑term liquidity. Article Title
• Positive Sentiment: Q4 results beat estimates (EPS -$0.25 vs. consensus -$0.39; revenue $22.6M vs. ~$21.7M), with narrower net loss and improved adjusted EBITDA — evidence management points to of early operational improvement. Article Title
• Positive Sentiment: Broker support: D. Boral Capital reaffirmed a Buy and maintained a high $14 target, which can attract momentum buyers given the large upside vs. current levels. Article Title
• Neutral Sentiment: Margins and cost discipline showed progress (Q4 gross margin ~78%, operating expenses down ~11% Q/Q), supporting the path to profitability but dependent on revenue re‑acceleration. Article Title
• Neutral Sentiment: Canaccord trimmed its price target (from $6 to $5) but kept a Buy rating — indicates mixed analyst views (some support, some more cautious on near‑term upside). Article Title
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below street consensus (~$94.1M), signaling slower top‑line growth and capping near‑term upside despite cost cuts. Article Title
• Negative Sentiment: New credit facility is relatively expensive (SOFR +7.0% with a 3.75% floor and 2% PIK option) and includes warrants — provides liquidity but raises interest cost and potential dilution. Article Title
• Negative Sentiment: Multiple insider sales (including CEO, general counsel and others) were disclosed for March 2 — adds perceived selling pressure and can weigh on sentiment, even if sales were small dollar amounts. Article Title

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on LUNG shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. D. Boral Capital reiterated a “buy” rating and set a $14.00 price target on shares of Pulmonx in a research report on Thursday. Finally, Canaccord Genuity Group decreased their price target on Pulmonx from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $5.38.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.